Gregory S Day

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/63903/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Practice guideline update summary: Mild cognitive impairment. Neurology, 2018, 90, 126-135.	1.5	1,263
2	Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology, 2018, 90, 777-788.	1.5	406
3	Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmunity Reviews, 2012, 11, 863-872.	2.5	155
4	Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology, 2018, 90, 789-800.	1.5	107
5	When dementia progresses quickly: a practical approach to the diagnosis and management of rapidly progressive dementia. Neurodegenerative Disease Management, 2014, 4, 41-56.	1.2	92
6	Abnormal Neurons in Teratomas in NMDAR Encephalitis. JAMA Neurology, 2014, 71, 717.	4.5	78
7	Anti-NMDA-Receptor Encephalitis: Case Report and Literature Review of an Under-Recognized Condition. Journal of General Internal Medicine, 2011, 26, 811-816.	1.3	77
8	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	4.9	72
9	Salience Network Resting-State Activity. JAMA Neurology, 2013, 70, 1249-53.	4.5	70
10	Patient characteristics and outcome associations in AMPA receptor encephalitis. Journal of Neurology, 2019, 266, 450-460.	1.8	60
11	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. Neurology, 2021, 97, 942-957.	1.5	58
12	Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia. Alzheimer Disease and Associated Disorders, 2017, 31, 87-93.	0.6	52
13	Sleep disturbances are common in patients with autoimmune encephalitis. Journal of Neurology, 2019, 266, 1007-1015.	1.8	52
14	LGI1 antibody encephalitis: acute treatment comparisons and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 309-315.	0.9	48
15	Investigating the role of the superior colliculus in active vision with the visual search paradigm. European Journal of Neuroscience, 2011, 33, 2003-2016.	1.2	44
16	Long-Term Cognitive Outcomes in Patients with Autoimmune Encephalitis. Canadian Journal of Neurological Sciences, 2018, 45, 540-544.	0.3	44
17	Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis. Journal of Neuroscience, 2018, 38, 3218-3229.	1.7	39
18	Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis. Neurology, 2021, 96, e2546-e2557.	1.5	38

#	Article	IF	CITATIONS
19	Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology, 2017, 88, 1273-1281.	1.5	34
20	The Longitudinal Earlyâ€onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimer's and Dementia, 2021, 17, 2043-2055.	0.4	34
21	Wernicke encephalopathy: a medical emergency. Cmaj, 2014, 186, E295-E295.	0.9	31
22	Searching for autoimmune encephalitis: Beware of normal CSF. Journal of Neuroimmunology, 2020, 345, 577285.	1.1	30
23	Lateral medullary syndrome: a diagnostic approach illustrated through case presentation and literature review. Canadian Journal of Emergency Medicine, 2014, 16, 164-170.	0.5	29
24	Discovery and validation of autosomal dominant Alzheimer's disease mutations. Alzheimer's Research and Therapy, 2018, 10, 67.	3.0	29
25	In vivo [¹⁸ F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology, 2018, 90, e896-e906.	1.5	27
26	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2021, 20, 615-626.	4.9	26
27	Author response: Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology, 2018, 91, 373-374.	1.5	25
28	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. NeuroImage: Clinical, 2020, 26, 102248.	1.4	24
29	Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus. Neurology, 2022, 98, 619-631.	1.5	24
30	Identifying priority outcomes that influence selection of disease-modifying therapies in MS. Neurology: Clinical Practice, 2018, 8, 179-185.	0.8	23
31	N-methyl-D-aspartate receptor encephalitis mediates loss of intrinsic activity measured by functional MRI. Journal of Neurology, 2016, 263, 1083-1091.	1.8	21
32	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. Brain, 2022, 145, 3594-3607.	3.7	20
33	Autoimmune Dementia. Seminars in Neurology, 2018, 38, 303-315.	0.5	19
34	The temporal onset of the core features in dementia with Lewy bodies. Alzheimer's and Dementia, 2022, 18, 591-601.	0.4	19
35	Anti-NMDA receptor encephalitis in children. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 112, 1229-1233.	1.0	18
36	Sleep Disturbances in Patients with Autoimmune Encephalitis. Current Neurology and Neuroscience Reports, 2020, 20, 28.	2.0	18

#	Article	IF	CITATIONS
37	Thiamine prescribing practices within universityâ€affiliated hospitals: A multicenter retrospective review. Journal of Hospital Medicine, 2015, 10, 246-253.	0.7	17
38	Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease. JAMA Neurology, 2016, 73, 1125.	4.5	17
39	Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults. Missouri Medicine, 2016, 113, 207-14.	0.3	15
40	Autoimmune Encephalitis With Multiple Autoantibodies. Neurologist, 2018, 23, 55-59.	0.4	14
41	Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. Alzheimer Disease and Associated Disorders, 2018, 32, 291-297.	0.6	12
42	Clinical and Paraclinical Measures Associated with Outcome in Cerebral Amyloid Angiopathy with Related Inflammation. Journal of Alzheimer's Disease, 2021, 80, 133-142.	1.2	12
43	Association of Acquired and Heritable Factors With Intergenerational Differences in Age at Symptomatic Onset of Alzheimer Disease Between Offspring and Parents With Dementia. JAMA Network Open, 2019, 2, e1913491.	2.8	11
44	<i>MAPT</i> R406W increases tau T217 phosphorylation in absence of amyloid pathology. Annals of Clinical and Translational Neurology, 2021, 8, 1817-1830.	1.7	11
45	Rethinking Outcomes in Leucine-Rich, Glioma-Inactivated 1 Protein Encephalitis. JAMA Neurology, 2017, 74, 19.	4.5	10
46	Reader response: Unintended consequences of Mayo paraneoplastic evaluations. Neurology, 2019, 93, 603-603.	1.5	10
47	<scp>LGI</scp> 1 autoantibodies associated with cerebellar degeneration. Neuropathology and Applied Neurobiology, 2014, 40, 645-649.	1.8	9
48	Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing. Alzheimer Disease and Associated Disorders, 2019, 33, 246-253.	0.6	9
49	Deciphering the factors that influence participation in studies requiring serial lumbar punctures. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12003.	1.2	9
50	Autoimmune Neurology. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	9
51	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. Neurobiology of Aging, 2021, 109, 43-51.	1.5	9
52	Deciphering the contributions of neuroinflammation to neurodegeneration: lessons from antibody-mediated encephalitis and coronavirus disease 2019. Current Opinion in Neurology, 2022, 35, 212-219.	1.8	8
53	Rapidly Progressive Dementia. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 901-936.	0.4	8
54	Teaching Neuro <i>Images</i> : Cerebral amyloid angiopathy–related inflammation presenting with isolated leptomeningitis. Neurology, 2017, 89, e66-e67.	1.5	7

#	Article	IF	CITATIONS
55	Flortaucipir (tau) PET in LGI1 antibody encephalitis. Annals of Clinical and Translational Neurology, 2021, 8, 491-497.	1.7	7
56	Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment. Neurology, 2022, 98, .	1.5	7
57	Testing for <i>N</i> -methyl- <scp>d</scp> -aspartate Receptor Autoantibodies in Clinical Practice. Canadian Journal of Neurological Sciences, 2020, 47, 69-76.	0.3	6
58	<i>GRIN1</i> polymorphisms do not affect susceptibility or phenotype in NMDA receptor encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e153.	3.1	5
59	Anti N-methyl-D-aspartate receptor encephalitis: a game-changer?. Expert Review of Neurotherapeutics, 2016, 16, 849-859.	1.4	5
60	The Road to Recovery: A Pilot Study of Driving Behaviors Following Antibody-Mediated Encephalitis. Frontiers in Neurology, 2020, 11, 678.	1.1	5
61	Autoimmune Encephalitis in First Episode Psychoses. Neurology, 2021, 97, 16-17.	1.5	5
62	Reversible Dementias. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 234-253.	0.4	5
63	Teaching Neuro <i>Images</i> : Recurrent SSPE presenting as Anton syndrome with cortical ribboning. Neurology, 2015, 85, e141-2.	1.5	4
64	Prevalence of Surgical Procedures at Symptomatic Onset of Prion Disease. JAMA Network Open, 2022, 5, e221556.	2.8	4
65	Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt–Jakob disease and autoimmune encephalitis. European Journal of Neurology, 2022, 29, 2905-2912.	1.7	4
66	A Case Study in the History of Neurology. Neurohospitalist, The, 2016, 6, 181-184.	0.3	3
67	Assessing the Reliability of Reported Medical History in Older Adults. Journal of Alzheimer's Disease, 2020, 78, 643-652.	1.2	3
68	Improving thiamine prescribing at an academic hospital network using the computerized provider order order entry system: a cohort study. CMAJ Open, 2020, 8, E383-E390.	1.1	3
69	An Elderly Man with Dementia. Clinical Chemistry, 2020, 66, 415-420.	1.5	3
70	Life after autoantibody-mediated encephalitis: optimizing follow-up and management in recovering patients. Current Opinion in Neurology, 2022, 35, 415-422.	1.8	3
71	The rapidly expanding world of rapidly progressive encephalopathy. Annals of Neurology, 2014, 75, 334-336.	2.8	2
72	Author response: In vivo [¹⁸ F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology, 2019, 92, 150-150.	1.5	2

#	Article	IF	CITATIONS
73	Amyloid and tau PET in sporadic earlyâ€onset Alzheimer's disease: Preliminary results from LEADS. Alzheimer's and Dementia, 2020, 16, e041613.	0.4	2
74	Sexâ€associated differences in pathology burden in earlyâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046532.	0.4	2
75	Statistical estimation and comparison of group-specific bivariate correlation coefficients in family-type clustered studies. Journal of Applied Statistics, 0, , 1-25.	0.6	2
76	Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient. Journal of Neuroimmunology, 2021, 352, 577474.	1.1	2
77	Three cases of Creutzfeldt–Jakob disease presenting with a predominant dysexecutive syndrome. Journal of Neurology, 2022, 269, 4222-4228.	1.8	2
78	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 0, , .	0.4	2
79	Cognitive decline in an older physician. Cmaj, 2015, 187, 750-754.	0.9	1
80	Oculopalatal Tremor Following Pontine Hemorrhage. Neurohospitalist, The, 2019, 9, 241-242.	0.3	1
81	Structural signature of sporadic Creutzfeldt–Jakob disease. European Journal of Neurology, 2019, 26, 1037-1043.	1.7	1
82	Serum neurofilament light chain uncovers neurodegeneration early in the course of Alzheimer's disease. Brain, 2020, 143, 3521-3522.	3.7	1
83	Measuring the cognitive costs of the COVID-19 pandemic. Molecular Neurodegeneration, 2021, 16, 67.	4.4	1
84	Rosary-Like Pattern Calcified Lesions: An Unusual Manifestation of Ipsilateral Carotid Artery Stenosis. Cerebrovascular Diseases, 2009, 28, 536-536.	0.8	0
85	How noise correlations impact the amount of information in superior colliculus: the analysis of a population with shared receptive fields. BMC Neuroscience, 2014, 15, .	0.8	0
86	P2-108: Differentiating corticobasal degeneration and Alzheimer disease by longitudinal clinical and cognitive features. , 2015, 11, P525-P525.		0
87	Fanning the Flames in Anti-N-methyl-D-aspartate Receptor Encephalitis. International Journal of Gynecological Pathology, 2015, 34, 401-402.	0.9	0
88	P2â€203: Phenotypic Similarities between Lateâ€Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Singleâ€Family Caseâ€Control Study. Alzheimer's and Dementia, 2016, 12, P698.	0.4	0
89	P4â€131: Evaluating the Contributions of Common Neurodegenerative Dementing Illnesses to Rapidly Progressive Dementia in the Outpatient Clinic. Alzheimer's and Dementia, 2016, 12, P1063.	0.4	0
90	P4-337: IN VIVO Quantification of Regional TAU Deposition in Patients with Progressive Posterior Cortical Dysfunction. , 2016, 12, P1163-P1164.		0

#	Article	IF	CITATIONS
91	[O3–03–01]: FLORTAUCIPIR TAUâ€PET SPECIFICITY IS MAINTAINED IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CREUTZFELDTâ€JAKOB DISEASE. Alzheimer's and Dementia, 2017, 13, P900.	0.4	0
92	[P3–257]: DECODING VARIABILITY IN AGEâ€ATâ€SYMPTOMATICâ€ONSET BETWEEN PARENTS AND CHILDREN SPORADIC ALZHEIMER DISEASE DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1041.	WITH	0
93	[ICâ€Pâ€180]: FLORTAUCIPIR TAUâ€PET SPECIFICITY IS MAINTAINED IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CREUTZFELDTâ€JAKOB DISEASE. Alzheimer's and Dementia, 2017, 13, P134.	0.4	Ο
94	ICâ€₽â€166: TAU PET IMAGING IN LGI1 ENCEPHALITIS: DECIPHERING THE CONTRIBUTORS TO COGNITIVE IMPAIRMENT IN AUTOIMMUNE ENCEPHALITIS. Alzheimer's and Dementia, 2019, 15, P131.	0.4	0
95	Overcoming Neurophobia With the Help of Peruvian Talking Bears. JAMA Neurology, 2020, 77, 291.	4.5	Ο
96	Tau kinetics in Alzheimer disease and primary tauopathies. Alzheimer's and Dementia, 2020, 16, e039109.	0.4	0
97	Increased white matter MRI T1 hypointensity volume in youngâ€onset Alzheimer's disease patients is not accounted for by age or cardiovascular risk factors. Alzheimer's and Dementia, 2020, 16, e045577.	0.4	0
98	Neurodegeneration in the Longitudinal Evaluation of Early Onset Alzheimer's Disease Study (LEADS) sample: Results from the MRI core. Alzheimer's and Dementia, 2020, 16, e046338.	0.4	0
99	Cross-Sectional and Longitudinal Comparisons of Biomarkers and Cognition Among Asymptomatic Middle-Aged Individuals with a Parental History of Either Autosomal Dominant or Late Onset Alzheimer Disease. SSRN Electronic Journal, 0, , .	0.4	Ο
100	Autoimmune synaptic protein encephalopathy syndromes and the interplay between mental heath, neurology and immunology. Health Science Inquiry, 2013, 4, .	0.1	0
101	Assessing the reliability of reported medical history in older adults. Alzheimer's and Dementia, 2020, 16, e042984.	0.4	Ο
102	A Neurologist's Practical Approach to Cognitive Impairment. Seminars in Neurology, 2021, 41, 686-698.	0.5	0
103	An unexpected risk: Surgical procedures are common in patients with prion disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0